To investigate whether the activation of JAK2/STAT3 signaling pathway resulted in upregulation of MMP9, VEGFa, and FGF2, JAK2 inhibitor AG490 was used to concurrently treat NIH/3T3 cells with melanoma cell-secreted exosomes. The gene discussed is VEGFA; the disease is melanoma.